KER-0193

N/A

Report date: 2025/03/12 16:22:46
NME

Base Information

Drug NameKER-0193
Drug Alias NameKER-0193
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated potassium channel modulators
TargetsVoltage-gated potassium channel
Therapy Area/IndicationsFragile X Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKaerus Bioscience Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKaerus Bioscience LtdLes Laboratoires Servier
Inactive CompaniesN/A
Active IndicationsFragile X Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A